A WESTERN Australian medical cannabis company reached a key milestone last week when it was granted a Therapeutic Goods Administration (TGA) Good Manufacturing Practices (GMP) licence for its recently commissioned manufacturing facility in the South West.
Little Green Pharma (LGP) is the sole ASX-listed medicinal cannabis company with in-house capability to manufacture TGA GMP-grade medicinal cannabis flower and oil products from its own cultivated flower for delivery into Australian and higher-margin European markets.
The GMP licencing of the company’s manufacturing facility is the culmination of a two-year regulatory strategy.
LGP now holds more than 20 State and Federal operating authorisations, allowing it to operate a fully in-house and vertically-integrated cannabis cultivation, production, manufacturing and wholesaling supply chain.
The company’s broad suite of licences and authorisations gives it the flexibility to respond to changing market conditions, focus on higher-margin…
